Mantle cell lymphoma (MCL): associated burden of illness and health care utilization in Ontario
Client: IQVIA Solutions Canada Inc.
Project ID: P2021-092 / 2022 0970 266 000
Research Question/Objectives: MCL is generally considered incurable, and a relapse is almost universal. With the recent and imminent emergence of novel therapies for MCL (such as immune and targeted therapies), understanding the MCL patient profile, real-world treatment patterns, burden of illness (BOI), and outcomes among patients with newly diagnosed MCL in Canada is essential to inform decision making, especially in the context of aging population. To address this need, a retrospective, real-world study will be conducted for elderly MCL patients with a focus on those in the first-line (1L) setting.
- Describe the real-world BOI and key clinical outcomes for newly diagnosed MCL patients aged ≥65 at diagnosis.
- Describe the overall survival (OS) and time to next treatment (TTNT) for newly diagnosed MCL ≥65 patients in the 1st LoT with systemic therapies.
- Determine and characterize drug treatment patterns for newly diagnosed MCL ≥65 patients in the 1st LoT with systemic therapies.
- Compare HCRU and direct healthcare costs of newly diagnosed MCL ≥65 patients in the 1st LOT of systemic therapy to controls.
- Describe the incidence and prevalence of newly diagnosed MCL ≥65 population
- April 2023